Life SciencesLiability
Get a quote

TL;DR

New Jersey is best known for its pharmaceutical corridor, but the state also carries a deep medical device and diagnostics base anchored by manufacturers headquartered here, including Becton Dickinson in Franklin Lakes. Device risk is underwritten differently from pharma: products liability is sized to device class, hospital and GPO purchase contracts drive additional-insured obligations, and connected or software-enabled devices pull cyber and Tech E&O into the product-liability picture. A-rated specialty markets structure these towers around FDA classification and contractual requirements rather than a single blanket policy.

New Jersey medical device

Medical Device Insurance for New Jersey Manufacturers

New Jersey occupies an unusual position in the life sciences economy. The state is synonymous with pharmaceuticals, but it also hosts a substantial concentration of medical device and diagnostics activity, from finished-device manufacturers to a deep supplier base of contract producers, component makers, and specialty processors. Becton Dickinson (BD), one of the largest medical device and diagnostics companies in the world, is headquartered in Franklin Lakes, and the surrounding Northern New Jersey corridor supports a dense network of firms feeding device and diagnostic supply chains.

That device presence carries an insurance profile distinct from the pharma corridor covered on its own page. A device manufacturer's exposure is defined by how its products are classified, how they reach hospitals through group purchasing organizations, and whether the product carries software or connectivity. Getting the coverage architecture right means matching each of those exposures to the correct policy trigger rather than assuming a general liability form will respond.

Get a quoteRun the Free Analyzer

Last updated 2026-07-13

Cluster shape

New Jersey's device and diagnostics cluster

The state's device economy sits alongside, and is often confused with, its pharmaceutical corridor. In practice they underwrite differently. Where pharma exposure centers on clinical development, manufacturing quality, and adverse-event liability tied to a compound, device exposure turns on physical product design, mechanical and material failure modes, and the contractual web that connects a manufacturer to hospitals and health systems.

Becton Dickinson's presence in Franklin Lakes is the most visible marker of that base, but the depth of the cluster is in the tiers beneath the large manufacturers: contract manufacturers, sterilization and packaging specialists, component and subassembly suppliers, and diagnostics firms. Each of these players faces products liability that flows downstream to the finished device, which makes vendor and additional-insured arrangements a central part of every program.

Diagnostics adds a further wrinkle. In-vitro diagnostic and laboratory products raise questions about false results, reagent performance, and the reliance clinicians place on a reported value. Those exposures behave more like a product-liability-and-professional hybrid than a straightforward manufactured-good claim, and the coverage response has to account for both.

Coverage architecture

How device coverage is structured

The foundation is products liability sized to device class. A Class I instrument, a Class II diagnostic or infusion device, and a Class III implantable each carry a different severity profile, and the products tower, typically expressed in market ranges from roughly $5M-$25M and higher for implantable or life-sustaining devices, is built to match. Where a device is still in development, clinical trial coverage tied to an Investigational Device Exemption (IDE) responds to subject-injury exposure during the study.

Contractual coverage is often the deciding factor in whether a program actually works. Hospital purchase contracts and GPO supplier agreements, including those administered through organizations such as Vizient, Premier, and HealthTrust, routinely require the manufacturer to name the hospital and the GPO as additional insureds for both products AND completed operations, on a primary and non-contributory basis, at specified limits. Product recall belongs in the structure as well, carried as a separate first-party trigger so that the cost of pulling and replacing product does not have to be litigated through a third-party liability form.

For connected and software-enabled devices, the product-liability vehicle shifts. A software-as-a-medical-device (SaMD) product or a connected instrument can cause patient harm through code, data, or a security failure rather than a physical defect, so cyber and Technology E&O function as a primary product-liability response for that exposure, not merely as an add-on. The most common structural gap we see is a blanket additional-insured endorsement that silently excludes products and completed operations, leaving the manufacturer technically insured but non-compliant with the very contract that required the endorsement.

Regulatory + market context

Regulatory and contractual context

FDA device classification is the organizing principle for the entire program. Class determines the premarket pathway, the severity assumptions underwriters apply, and the size of the products tower, which is why an accurate classification for each product line is the starting point for any credible submission. Devices moving through an IDE study need clinical trial coverage aligned to the protocol before enrollment begins.

On the commercial side, the contracts a New Jersey manufacturer signs with hospitals and GPOs effectively dictate the insurance terms. Requirements for additional-insured status covering products and completed operations, primary and non-contributory wording, and minimum limits are non-negotiable conditions of doing business with most health systems. A program that reads well on its own but fails to satisfy those clauses will stall the contract, so the certificate and endorsement language has to be verified against each agreement rather than assumed.

Frequently asked

Common questions from New Jersey medical device operators

What makes New Jersey medical device insurance distinct from the state's pharma coverage?

New Jersey carries a real device and diagnostics base alongside its pharmaceutical corridor, with major manufacturers such as Becton Dickinson headquartered in Franklin Lakes and a deep supplier network across Northern New Jersey. Device risk underwrites differently from pharma: products liability is driven by FDA device class and physical or software failure modes rather than by a compound's clinical profile, and hospital and GPO purchase contracts create additional-insured obligations that pharma programs rarely face. Treating a device manufacturer as a pharma account, or the reverse, tends to leave real gaps.

How is the products liability tower sized for a device manufacturer?

It is sized to device class. A Class I instrument, a Class II diagnostic or infusion product, and a Class III implantable each carry different severity assumptions, and the tower is built to match, with market-typical ranges commonly running from around $5M-$25M and higher for implantable or life-sustaining devices. Underwriters also weigh the installed base, the patient contact the device has, and whether it is life-sustaining, so an accurate classification for each product line is the foundation of the submission.

What do hospital and GPO contracts require from a device supplier's insurance?

Hospital purchase contracts and GPO supplier agreements, including those run through organizations such as Vizient, Premier, and HealthTrust, generally require the manufacturer to name the hospital and the GPO as additional insureds for both products AND completed operations, on a primary and non-contributory basis, at specified limits. The frequent failure point is a blanket additional-insured endorsement that quietly excludes products and completed operations, which leaves the supplier out of compliance with the contract it just signed. The endorsement language has to be checked against each agreement.

How are connected or software-based devices covered?

For software-as-a-medical-device (SaMD) products and connected instruments, patient harm can arise from code, data handling, or a security breach rather than a physical defect, so cyber and Technology E&O act as a primary product-liability vehicle for that exposure rather than a secondary add-on. A traditional products liability form built around manufactured-good defects may not respond cleanly to a software or connectivity failure. The program should coordinate the products tower with cyber and Tech E&O so the two do not leave a gap between them.

Medical device insurance practice →Device products liability →New Jersey pharma corridor →New Jersey state guide →

Free coverage review

A specialist will reach out by end of business day.

Programs placed through A-rated specialty markets. Send your contract, insurance schedule, or current COI - a specialist returns a clause-by-clause read by end of business day.

Get my quote

Specifically for New Jersey medical device operators.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.